Microsoft Office Medical
Resume:
JIANXUE LI
*** ***** ******, **** ****, Revere, MA 02151 • *********@*******.*** • 857-***-****
BIOMEDICAL / PHARMACEUTICAL R&D SCIENTIST
I have over 15-year experience of spearheading or collaborating on groundbreaking / translational research in biotech and pharmaceutical fields at Harvard Medical School, including pathogenic molecules and therapeutic target/drug discovery, with multiple awards and numerous publications.
I am a hands-on expert in:
Human tumor stem cell-based high content/throughput screening for therapeutic target/lead;
3D organoids from hESC/iPSC; Primary cell assay; Cell line generation; Flow cytometry; FACS;
Drug PK/PD modeling; Drug toxicity assay in vivo & in vitro; Drug electrophysiological test;
DNA purification, cloning & sequencing; Viral vector-based transduction; RNAi; PCR; qRT-PCR;
Western blot; ELISA; Protein purifying; Receptor-ligand binding; Luminex; Radioimmunoassay;
Enzymatic kinetics; Metabolite assay; Chemical analysis; Chromatography (TLC, HPLC); MS;
Tissue transparency (CLARITY); Immunohistochemistry; Confocal and Light-Sheet microscopy;
Animal models of brain tumors (xenograft/syngeneic), metabolic, neurological & retinal disorders.
My expertise involves:
Molecular and Cell Biology • Biochemistry • Pharmacology • Oncology • Immunology • Neurobiology
• Animal Modeling • Histopathology • Toxicology • Virology • Systems Biology • Analytical Chemistry
MAJOR PROFESSIONAL EXPERIENCE
Harvard Medical School, Harvard University, Boston, MA (Instructor) 10/2002 – 06/2016
The University of Toronto, Toronto, Canada (Research Associate) 10/1998 – 09/2002
MIT, Cambridge, MA (Postdoctoral Fellow) 09/1996 – 09/1998
Major Responsibilities:
Spearhead development & implementation of biomedical & therapeutic target/drug projects.
Conduct hands-on experiments, analyze data, and prepare publication and presentation.
Perform laboratory-training program for research assistants and medical students.
Representative Achievements:
Achieved a major breakthrough by identifying pathogenic process and molecular mechanism of neurological & metabolic diseases (ataxia, epilepsy, Fragile X, AD, PD, ALS) and brain tumors.
Improved scientific knowledge of therapeutic target (VEGFR) / lead compound (peptidomimetic) by developing and deploying a unique blend of translational medicine strategies.
Earned multiple awards in recognition of my outstanding performance and research promise, such as the William Randolph Hearst Fund, the Nancy Lurie Marks Family Foundation, the Fragile X Syndrome Foundation, and the Brain Sciences & Metabolism Charitable Trust, etc.
Published over 80 peer-reviewed research articles on top journals, such as Science Transl Med, Neuron, PNAS USA, J Cell Biol, Stem Cells, and J Neurosci, etc.
Key Research Projects:
Therapeutic Target Identification:
1) Targeting VEGF receptors in brain tumor and retinal angiogenesis disease. (04/2011-10/2015)
2) Deglutamylase-associated posttranslational modification in AD. (06/2013-Present)
3) Proteolytic metabolism in inherited cerebellar ataxia and autism. (07/2003-06/2010)
4) GluR, synaptic plasticity & neurotransmission in Fragile X syndrome. (01/1999-06/2002)
5) Connexin 32-mediated gap junction coupling in epilepsy models. (10/1998-06/2003)
Drug Screening and Stem Cell Therapy:
1) 3D cultures of organoids and CSCs for anti-tumor drug screening. (06/2015-Present)
2) Neural stem cell therapy for metabolic disease, trauma, ataxia & ALS. (10/2002-09/2012)
3) Lipidomics signature (glycerophospholipid profiling) of retinal stem cells. (01/2001-06/2007)
4) Molecular pathway controlling hESC or iPSC differentiation to neural cells. (02/2012-04/2015)
5) Phosphoproteomics and chromatin profiling of hESCs and iPSCs. (07/2013-04/2016)
Basic Neurobiological Research:
1) Entire brain transparency (CLARITY) and 3D tissue visualization (LSM). (07/2014-Present)
2) Roles of NF-κB signaling and MAP in neuronal dendrite development. (01/2006-10/2010)
3) Excess tPA and downstream molecules regulating synaptic transmission. (06/2008-10/2012)
4) VDAC malfunctions inducing mitochondria-associated apoptosis. (07/2010-06/2014)
5) NGF, lipid metabolism & cell membrane formation in neural differentiation. (09/1996-12/2000)
REPRESENTATIVA ARTICELS (from 80 peer-reviewed papers)
1.Abelin JG, Patel J, Lu X, Feeney CM, Fagbami L, Creech AL, Hu R, Lam D, Davison D, Pino L, Qiao JW, Kuhn E, Officer A, Li J, et al. Reduced-representation phosphosignatures measured by quantitative targeted MS capture cellular states and enable large-scale comparison of drug-induced phenotypes. Mol Cell Proteomics 2016; 15:1622-1641.
2.Sidman RL, Li J, et al. The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci Transl Med 2015; 7:309ra165.
3.Li J, et al. Tissue plasminogen activator regulates Purkinje neuron development and survival. Proc Natl Acad Sci USA 2013; 110:E2410-E2419.
4.Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, Lachyankar MB, Marconi M, Li J, et al. Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci Transl Med 2012; 4:165ra164.
5.Kim KS, Lee HJ, Jeong HS, Li J, et al. Self-renewal induced efficiently, safely and effective therapeutically with one regulatable gene in a human somatic progenitor cell. Proc Natl Acad Sci USA 2011; 108:4871-4881.
6.Li J, et al. Nna1 mediates Purkinje cell dendritic growth via lysyl oxidase propeptide and NF-кB signaling. Neuron 2010; 68:46-60.
7.Jäderstad J, Jäderstad LM, Li J, et al. Communication via gap junctions underlies early functional and anti-degenerative interactions between grafted neural stem cells and host cells. Proc Natl Acad Sci USA 2010; 107:5184-5189.
8.Staquicini FI, Dias-Neto E, Li J, et al. Discovery of a functional protein complex of netrin-4, laminin gamma1 chain, and integrin alpha6beta1 in mouse neural stem cells. Proc Natl Acad Sci USA 2009; 106:2903-2908.
9.Li J, et al. Unique glycerophospholipid signature in retinal stem cells correlates with enzymatic functions of diverse long-chain acyl-CoA synthetases. Stem Cells 2007; 25:2864-2873.
10.Ma Y, Li J, et al. Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. J Cell Biol 2006; 175:209-215.
11.Li J, et al. Neural stem cells rescue nervous Purkinje neurons by restoring molecular homeostasis of tissue plasminogen activator and downstream targets. J Neurosci 2006; 26:7839-7848.
12.Li J, et al. Purkinje neuron degeneration in nervous mutant mouse is mediated by a metabolic pathway involving excessive tissue plasminogen activator. Proc Natl Acad Sci USA 2006; 103:7847-7852.
13.Li J, et al. Epileptiform activity in hippocampal slice cultures exposed chronically to bicuculline: increased gap junctional function and expression. J Neurochem 2003; 86:687-699.
14.Li J, et al. Reduced cortical synaptic plasticity and GluR1 expression associated with Fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002; 19:138-151.
15.Li J, et al. Upregulation of gap junction connexin 32 with epileptiform activity in the isolated mouse hippocampus. Neuroscience 2001; 105:589-598.
PROFESSIONAL AFFILIATIONS
International Society for Cell Therapy • International Society for Stem Cell Research
Society for Neuroscience • International Society for Fragile X Syndrome
COMPUTER SKILL
ImageJ; Zeiss LSM; PhotoShop; Neurolucida; Stereo Investigator; Quantity One; Gene Runner; BLAST; Microarray Suite; Data Mining Tool; Pclamp; Axotape; DeO; Softmax; Microsoft Office
EDUCATION
PhD/MD (Molecular and Biochemical Toxicology), Tongji Medical University, China
Contact this candidate